Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology explains a common question that’s usually asked regarding the CASTOR/POLLUX study, which is whether or not you can split the dosing of daratumumab. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 8006: Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status
Advertisement